153607-45-5 Usage
Description
1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]piperazine, also known as SB-399885, is a complex chemical compound belonging to the piperazine class. It is characterized by its benzodioxin and indenyl moieties, which contribute to its unique properties. 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]piperazine functions as a selective antagonist for the 5-HT6 serotonin receptor, making it a subject of interest for its potential therapeutic applications in the treatment of neurological and psychiatric disorders.
Uses
Used in Pharmaceutical Industry:
1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]piperazine is used as a therapeutic agent for neurological and psychiatric disorders due to its selective antagonist activity at the 5-HT6 serotonin receptor. Its potential to improve cognitive function and memory makes it a valuable candidate for further research and development in the treatment of conditions such as Alzheimer's disease, schizophrenia, and other cognitive impairments.
Used in Research and Development:
In the field of scientific research, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]piperazine serves as a valuable tool for investigating the role of the 5-HT6 receptor in various physiological and pathological processes. Understanding its specific interactions and mechanisms of action can lead to the development of novel therapeutic strategies targeting this receptor.
Used in Drug Design and Development:
The unique properties of 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]piperazine make it a promising starting point for the design and development of new drugs targeting the 5-HT6 receptor. Its complex chemical structure can be further modified and optimized to enhance its therapeutic potential and selectivity, leading to the creation of more effective treatments for neurological and psychiatric disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 153607-45-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,3,6,0 and 7 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 153607-45:
(8*1)+(7*5)+(6*3)+(5*6)+(4*0)+(3*7)+(2*4)+(1*5)=125
125 % 10 = 5
So 153607-45-5 is a valid CAS Registry Number.
153607-45-5Relevant articles and documents
Characterization of potent and selective antagonists at postsynaptic 5- HT(1A) receptors in a series of N4-substituted arylpiperazines
Peglion,Canton,Bervoets,Audinot,Brocco,Gobert,Le Marouille-Girardon,Millan
, p. 4044 - 4055 (2007/10/03)
Benzocycloalkyl and benzocycloalkenyl moities linked, directly or via an alkyl chain, to oxygen-bearing heteroarylpiperazines were synthesized, in an attempt to obtain potent and selective antagonists at postsynaptic 5-HT(1A) receptors. From the numerous arylpiperazines described in the literature, 1- (2,3-dihydro-1,4-benzodioxin-5-yl)piperazine (3a) was chosen as a model of an arylpiperazine in view of its selectivity for 5-HT(1A) receptors versus α1- , α2-, and β-adrenergic receptors, as well as dopamine D1 and D2 receptors. Two other closely-related arylpiperazines, 1-(1,5-benzodioxepin- 6-yl)piperazine (3b) and 1-(benzofuran-7-yl)piperazine (3c), were also examined in this study. All compounds showed high affinity at 5-HT(1A) sites (8.10 ≤ pK(i)s ≤ 9.35), and the majority behaved as antagonists in viva in blocking the hypothermia induced by the 5-HT(1A) agonist 8-OH-DPAT in the absence of a marked effect alone at equivalent doses. An in vivo evaluation of dopamine D2 receptor antagonist properties revealed that the majority of compounds was devoid of activity at this site, in marked contrast to BMY 7378 which displayed virtually no selectivity far 5-HT(1A) versus dopamine D2 receptors. Moreover, six compounds of the present series, 8, 10, 11, 14, 25, and, 37, showed > 10-fold selectivity in vitro for 5-HT(1A) versus α1- adrenergic receptors. Compound 14 displayed an optimal compromise between potency (pK(i) = 8.75), marked antagonist activity, and selectivity toward α1-adrenergic (81-fold) and dopamine D2 (195-fold) receptors. These characteristics clearly distinguish 14 from previously-reported ligands such as the postsynaptic 5-HT(1A) antagonist BMY 7378 and the weak partial agonist NAN 190 which, in contrast to the compounds of this series, belong to the well-exemplified class of imido derivatives of (o-methoxyphenyl)piperazines. The availability of 14 (S 15535) should facilitate the further elucidation of the functional role and potential therapeutic significance of 5-HT(1A) receptors.
